Yes BP is worrisome, I smell extended safety studies... and while HDL raising is not yet validated based on outcomes studies, I disagree it is a meanlingless endpoint. Investors will see a drug that raises HDL and lowers LDL as a true blockbuster and certainly imaging study results will be available much sooner so impact to pps is shorter term, even w/o approval. Very rosy picture except for that "worrisome" BP raising......
anyone remember ESPR? I don't very well but I do remember measurement was a bit of an issue- didn't take much change to be important. Also seems size matters but so does quality of the endothelium.
So, whatever happened to ESPR? It is too bad you can't get charts on things like this, or the ones that went under, to get a good back-test on what worked and what didn't...
Market Data 
Markets 
AI
